'Hush money' tied to Purdue settlement; the fallout from Gilead's latest deals

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Dozens of towns and counties object to 'hush money' tied to Purdue opioid settlement By Ed Silverman Toby Talbot/AP The towns and counties argue that nearly $277 million of the settlement will go to eight states that negotiated a revised $6 billion deal. Read More STAT+: Gilead's Dan O'Day is pharma's most charming executive — but with his deals falling apart, charm may not be enough By Matthew Herper Emilie Pickering for STAT The news that Gilead dropped about its drug breast cancer drug Trodelvy was the latest in a string of disappointments. Read More STAT+: AbbVie settles litigation with another drug maker over a biosimilar version of Humira By Ed Silverman Aram Boghosian for STAT The settlement is only the latest deal in which AbbVie has successfully delayed would-be rivals from marketing their own versions of the blockbuster drug. Read More Sponsor content by STAT TRIALS PULSE STAT Trials Pulse redefines clinical trials intelligence with a new tool powered by artificial intelligence and STAT's biotech team STAT and AI company Applied XL have partnered to develop a new clinical trials intelligence platform, STAT Trials Pulse. Combining machine learning and feedback from STAT's trusted newsroom, the platform allows you to monitor the clinical trials landscape and surface critical insights and trends more easily than ever before. Learn more at statnews.com/trials-pulse, or skip the details and start your four-week free trial at trials.appliedxl.com. Nurses, more powerful and visible after Covid, capitalize on new clout in Washington By Lev Facher Spencer Platt/Getty Images Empowered by their role fighting Covid, nurses are planning a march on Washington, and pushing lawmakers and Biden to improve their pay. Read More Wednesday, March 9, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser